Lacosamide.
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.
Perucca
Emilio
E
Department of Internal Medicine and Therapeutics and Institute of Neurology, IRCCS C Mondino Foundation, University of Pavia, Italy. perucca@unipv.it
Yasothan
Uma
U
Clincke
Gilbert
G
Kirkpatrick
Peter
P
D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy*; D006801:Humans; D000078334:Lacosamide; D016032:Randomized Controlled Trials as Topic; D051381:Rats
D000081:Acetamides; D000700:Analgesics; D000927:Anticonvulsants; D000078334:Lacosamide